Your browser doesn't support javascript.
loading
Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models.
Karuppagounder, Saravanan S; Alim, Ishraq; Khim, Soah J; Bourassa, Megan W; Sleiman, Sama F; John, Roseleen; Thinnes, Cyrille C; Yeh, Tzu-Lan; Demetriades, Marina; Neitemeier, Sandra; Cruz, Dana; Gazaryan, Irina; Killilea, David W; Morgenstern, Lewis; Xi, Guohua; Keep, Richard F; Schallert, Timothy; Tappero, Ryan V; Zhong, Jian; Cho, Sunghee; Maxfield, Frederick R; Holman, Theodore R; Culmsee, Carsten; Fong, Guo-Hua; Su, Yijing; Ming, Guo-li; Song, Hongjun; Cave, John W; Schofield, Christopher J; Colbourne, Frederick; Coppola, Giovanni; Ratan, Rajiv R.
Afiliação
  • Karuppagounder SS; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Alim I; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Khim SJ; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Bourassa MW; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Sleiman SF; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • John R; Department of Psychology, University of Alberta, Edmonton, Alberta T6G 2E9, Canada.
  • Thinnes CC; Department of Chemistry, University of Oxford, OX1 3TA Oxford, UK.
  • Yeh TL; Department of Chemistry, University of Oxford, OX1 3TA Oxford, UK.
  • Demetriades M; Department of Chemistry, University of Oxford, OX1 3TA Oxford, UK.
  • Neitemeier S; Institut fuer Pharmakologie and Klinische Pharmazie, Phillips-Universitaet Marburg, D 35032 Marburg, Germany.
  • Cruz D; Department of Biochemistry, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Gazaryan I; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Killilea DW; Children's Hospital of Oakland, Oakland, CA 94609, USA.
  • Morgenstern L; Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Xi G; Department of Neurosurgery, University of Michigan, Ann Arbor, MI 48109, USA.
  • Keep RF; Department of Neurosurgery, University of Michigan, Ann Arbor, MI 48109, USA.
  • Schallert T; Department of Psychology, University of Texas at Austin, Austin, TX 78712, USA.
  • Tappero RV; Photon Sciences Directorate, Brookhaven National Laboratory, Upton, NY 11973, USA.
  • Zhong J; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Cho S; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Maxfield FR; Department of Biochemistry, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Holman TR; Chemistry and Biochemistry, Department, University of California at Santa Cruz, Santa Cruz, CA 95064, USA.
  • Culmsee C; Institut fuer Pharmakologie and Klinische Pharmazie, Phillips-Universitaet Marburg, D 35032 Marburg, Germany.
  • Fong GH; Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, USA.
  • Su Y; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Ming GL; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Song H; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Cave JW; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA.
  • Schofield CJ; Department of Chemistry, University of Oxford, OX1 3TA Oxford, UK.
  • Colbourne F; Department of Psychology, University of Alberta, Edmonton, Alberta T6G 2E9, Canada.
  • Coppola G; Department of Psychiatry, University of California at Los Angeles, CA 90095, USA.
  • Ratan RR; Sperling Center for Hemorrhagic Stroke Recovery, Burke Medical Research Institute, White Plains, NY 10605, USA. Feil Family Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY 10065, USA. rrr2001@med.cornell.edu.
Sci Transl Med ; 8(328): 328ra29, 2016 Mar 02.
Article em En | MEDLINE | ID: mdl-26936506
Disability or death due to intracerebral hemorrhage (ICH) is attributed to blood lysis, liberation of iron, and consequent oxidative stress. Iron chelators bind to free iron and prevent neuronal death induced by oxidative stress and disability due to ICH, but the mechanisms for this effect remain unclear. We show that the hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) family of iron-dependent, oxygen-sensing enzymes are effectors of iron chelation. Molecular reduction of the three HIF-PHD enzyme isoforms in the mouse striatum improved functional recovery after ICH. A low-molecular-weight hydroxyquinoline inhibitor of the HIF-PHD enzymes, adaptaquin, reduced neuronal death and behavioral deficits after ICH in several rodent models without affecting total iron or zinc distribution in the brain. Unexpectedly, protection from oxidative death in vitro or from ICH in vivo by adaptaquin was associated with suppression of activity of the prodeath factor ATF4 rather than activation of an HIF-dependent prosurvival pathway. Together, these findings demonstrate that brain-specific inactivation of the HIF-PHD metalloenzymes with the blood-brain barrier-permeable inhibitor adaptaquin can improve functional outcomes after ICH in several rodent models.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Oxigênio / Encéfalo / Pró-Colágeno-Prolina Dioxigenase / Hemorragias Intracranianas / Fator 4 Ativador da Transcrição / Terapia de Alvo Molecular / Neurônios Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Oxigênio / Encéfalo / Pró-Colágeno-Prolina Dioxigenase / Hemorragias Intracranianas / Fator 4 Ativador da Transcrição / Terapia de Alvo Molecular / Neurônios Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos